In Case This Article Makes You Wonder, At All. . . .

July 13, 2009 · Leave a Comment


I declare that this site receives no sponsorship, free product, nor even free data-streams, in return for anything written here. I do not use any of the medications mentioned on this site — nor do I have any persistent medical conditions which otherwise might be treatable, or treated, with any such medications, were I inclined to go the homeopathic route (which route, in general, I am almost never inclined to take — except for some honey-lemon tea — for the rare sore throat). So, these are solely my opinions, unless otherwise noted (as being contributed by Salmon, Wolf or PM, for example).

Just so we’re clear (as if it weren’t painfully obvious), there is none of this going on, here:

. . . .But unlike postings in most journalism outlets or independent review sites, most companies can be assured that there will not be a negative review: if she does not like a product, she simply does not post anything about it.

The proliferation of paid sponsorships online has not been without controversy. Some in the online world deride the actions as kickbacks. Others also question the legitimacy of bloggers’ opinions, even when the commercial relationships are clearly outlined to readers.

And the Federal Trade Commission is taking a hard look at such practices and may soon require online media to comply with disclosure rules under its truth-in-advertising guidelines. . . .

Indeed. A rather goofy comment in the Vertex thread, below, reminded me that I ought to make this clear, perhaps once very year: I own no Vertex, Abbott, Merck, AstraZeneca or J&J stock, either — nor am I short any of these names (including Schering-Plough), at the moment.

Categories: Uncategorized
Tagged:

I’ll Live Blog Portions of Johnson and Johnson’s Q2 Earnings Webcast, Tommorow. . . .

July 13, 2009 · Leave a Comment


Or, at least, portions of it — related to the Remicade/Simponi arbitration pending with Schering-Plough; any observations on the recent J&J v. Abbott Remicade $1.67 Billion patent verdict in Texas; and any news on the Abbott v. J&J Simponi patent litigation now pending in Massachusetts. It will all live-stream right here, tomorrow morning, from this link:

. . . .Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 14, 2009, to review second-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor Relations, will host the call. . . .

In answer to the very-first question asked on the call, Dominic Caruso, Vice President, Finance and Chief Financial Officer took a “no comment” on the arbitration’s outlook, other than to say that J&J has filed for arbitration, and it is awaiting the beginning of it. . . .

Categories: Uncategorized
Tagged: